BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GE Healthcare and Eisai Inc. (ESALF.PK) to Partner on Alzheimer's Disease Research


4/24/2013 11:35:55 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHALFONT ST. GILES, England--(BUSINESS WIRE)--GE Healthcare today announced a research collaboration agreement with Eisai Inc. for use of the GE Healthcare investigational PET amyloid imaging agent, [18F]flutemetamol, to help select patients for a phase I clinical trial being conducted by Eisai. The trial evaluates Eisai’s investigational compound E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor for the potential treatment of Alzheimer’s disease (AD). The accumulation of beta amyloid in the brain is believed to play a role in the degeneration of neurons and is one of several pathological characteristics implicated in the development of AD.

“Alzheimer’s disease is an important area of research for the industry and specifically for GE Healthcare,” said Pascale Witz, President and CEO of GE Healthcare, Medical Diagnostics. “This partnership may ultimately support the market entry of important therapies, and potentially, expedited time to market because the right patients have been identified for participation in clinical trials. Under terms of the agreement, GE Healthcare’s proprietary software technology will be used during the trial to help support imaging data analysis.”

"Eisai has a long-standing commitment to Alzheimer's disease," said Lynn Kramer, MD, Chief Clinical Officer and President of the Neuroscience and General Medicine Product Creation Unit at Eisai Product Creation Systems. "Imaging plays a key role in our efforts to better understand the progression of the disease and identify potential patients for our clinical trials. Through this collaboration, Eisai hopes to bring important new treatment options to patients and caregivers who are affected by this devastating disease."

GE Healthcare takes a comprehensive approach to understanding a variety of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, post-traumatic stress disorder, concussion, traumatic brain injury and Multiple Sclerosis through its ongoing research to uncover the causes, risks, and physical effects of these conditions. By collaborating with the pharmaceutical industry to assist in their development of the next generation of therapies to treat these disorders and working with potential partners in the industry, GE Healthcare can provide imaging support for clinical trials of therapeutic agents.

For more information about Eisai’s Phase I trial, which is currently recruiting participants, please visit www.ClinicalTrials.gov.

ABOUT GE HEALTHCARE

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

For our latest news, please visit http://newsroom.gehealthcare.com

Contacts

GE Healthcare

Aleisia Gibson

609 514 6046 (office)

201 289 3832 (mobile)

Aleisia.gibson@ge.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES